Class 1. Drug-induced and Toxin-induced Pulmonary Hypertension

Amonafide Targeting NTSR1-PI3K/AKT/mTOR Signaling Attenuates Vascular Remodeling in Pulmonary Arterial Hypertension

Yong‐Jian Zhu, Jie‐Jian Kou, Ya‐Cong Bo, Meng‐Jie Zhang, Xin Fan, Lu‐Ling Zhao, Yi Yan, Hong Da Zhang, Wen‐Hui Wu, Ping Yuan, Yan Liu, Jun‐Zhuo Shi, Xiao‐Bin Pang, Yang‐Yang HeFirst Affiliated Hospital of Zhengzhou University. Huaihe Hospital and Henan University. Zhengzhou University. Shanghai Children’s Medical Center and Shanghai Jiao Tong University School of Medicine. Fuwai Hospital and Peking Union Medical College. Shanghai Pulmonary Hospital and School of Medicine Tongji University. China Journal of the American Heart AssociationJ Am Heart Assoc

Amonafide Targeting NTSR1-PI3K/AKT/mTOR Signaling Attenuates Vascular Remodeling in Pulmonary Arterial Hypertension Read More »

Efficacy and safety of fenfluramine in Dravet syndrome; A monocentric, observational study focused on initial dose, blood concentration, and reduction of concomitant medications

Akihiro Iguchi, Tokito Yamaguchi, Yu Tsuyusaki, Hideyuki Otani, Satoshi Mizutani, Mitsuhiro Miyashita, Manami Yabe, Katsumi ImaiNHO Shizuoka Institute of Epilepsy and Neurological Disorders and Asahi General Hospital. Japan Epilepsy and BehaviorEpilepsy Behav 2026; DOI: 10.1016/j.yebeh.2026.111070 AbstractObjective: To evaluate the optimal initial dose, efficacy, and adverse events of fenfluramine (FFA) in the treatment of intractable epilepsy in Dravet

Efficacy and safety of fenfluramine in Dravet syndrome; A monocentric, observational study focused on initial dose, blood concentration, and reduction of concomitant medications Read More »

Inflachromene attenuates monocrotaline-induced pulmonary arterial hypertension by suppressing the HMGB1-TLR4/RAGE-NF-κB signaling pathway

Yueru Wang, Dina Nuerlan, Bilali Paizula, Yimuran Kawulijiang, Jiyao Chen, Hong Zhu, Wentao Xiao, Zhayier Tueraili, Guoming ZhangFirst Affiliated Hospital of Xinjiang Medical University. Second Affiliated Hospital of Xinjiang Medical University. First Affiliated Hospital of Shihezi University.China International ImmunopharmacologyInt Immunopharmacol 2026; DOI: 10.1016/j.intimp.2026.116712 AbstractPulmonary arterial hypertension (PAH) is a debilitating and fatal cardiovascular disorder marked by

Inflachromene attenuates monocrotaline-induced pulmonary arterial hypertension by suppressing the HMGB1-TLR4/RAGE-NF-κB signaling pathway Read More »

R213G-Mediated Redistribution of EC-SOD Protects Against Sugen-Hypoxia Pulmonary Hypertension in Mice

Daniel Colon Hidalgo, Caitlin V. Lewis, Thi‐Tina N. Nguyen, Janelle N. Posey, Samuel D. Burciaga, Nathan Dee, Christina Sul, Julie Harral, David Irwin, Cassidy Delaney, Eva S. NozikUniversity of Colorado Anschutz Medical Campus. United States Pulmonary CirculationPulm Circ 2026; 16: DOI: 10.1002/pul2.70307 AbstractPulmonary hypertension (PH) is a progressive and life-threatening disease characterized by pulmonary vascular remodeling

R213G-Mediated Redistribution of EC-SOD Protects Against Sugen-Hypoxia Pulmonary Hypertension in Mice Read More »

From standard to individualized diazoxide therapy in congenital hyperinsulinism: a narrative review

Teresa Wong, Daniel Chan, Cherie Chua, Wenqi Cher, Selina Lim, Suresh Chandran, Fabian YapKK Women’s and Children’s Hospital. Duke NUS Medical School. Singapore Frontiers in PharmacologyFront Pharmacol 2026; 17:DOI: 10.3389/fphar.2026.1781424 AbstractPurpose: Congenital hyperinsulinism (CHI) is the commonest cause of persistent hypoglycaemia in neonates and infants (blood glucose <3.0 mmol/L in first 2-3 days of life; <3.5 mmol/L

From standard to individualized diazoxide therapy in congenital hyperinsulinism: a narrative review Read More »

Practical Recommendations for Cardiology Follow-Up in Patients Treated with Fenfluramine Based on Expert Opinion and Clinical Experience

Antonio Gil‑Nagel, Leopoldo Pérez de la Isla, Elena Sanz Pascual, Enrique J. Balbacid Domingo, Juan J. García PeñasRuber Internacional Hospital. San Carlos Clinical Hospital. La Paz Children’s Hospital and La Paz University Hospital. Universidad Europea de Madrid. Spanish Society of Cardiology. Niño Jesús University Children’s Hospital.Spain Neurology and TherapyNeurol Ther 2026; DOI: 10.1007/s40120-026-00930-2 AbstractIntroduction: Fenfluramine (FFA) is

Practical Recommendations for Cardiology Follow-Up in Patients Treated with Fenfluramine Based on Expert Opinion and Clinical Experience Read More »

Lamp Oil Poisoning: Pulmonary Hypertension Following Oil Aspiration Successfully Treated with Inhaled Nitric Oxide

Demet Tosun, Ilyas Bingöl Nihal AkçayIstanbul Kanuni Sultan Suleyman Training and Research Hospital.Turkey Klinische PädiatrieKlin Padiatr 2026; DOI: 10.1055/a-2814-3185 AbstractAbstract Not Available CategoryClass I. Drug-induced and Toxin-induced Pulmonary HypertensionMedical Therapy. Efficacy or Lack of Efficacy Age Focus: Pediatric Pulmonary Vascular Disease Fresh or Filed Publication: Fresh (PHresh). Less than 1-2 years since publication Article Access Free

Lamp Oil Poisoning: Pulmonary Hypertension Following Oil Aspiration Successfully Treated with Inhaled Nitric Oxide Read More »

Cleavage and Polyadenylation Specificity Factor Subunit 5 Regulates Pulmonary Artery Smooth Muscle Expansion and Hypoxic Response

Scott D. Collum, Lisha Zhu, Tingting W. Mills, Rene Girard, Jamie Tran, Tinne C. J. Mertens, Cory Wilson, Nancy Wareing, Erik E. Suarez, Howard J. Huang, Rahat Hussain, Bindu Akkanti, Wenjin J. Zheng, Hari K. Yalamanchili, Bela Patel, Eric J. Wagner, Sandeep Agarwal, Harry Karmouty-QuintanaMcGovern Medical School University and McWilliams School of Biomedical Informatics of

Cleavage and Polyadenylation Specificity Factor Subunit 5 Regulates Pulmonary Artery Smooth Muscle Expansion and Hypoxic Response Read More »

Preparation of 18β-Glycyrrhetinic Acid Liposome and Its Therapeutic Effect on Pulmonary Arterial Hypertension

Yanmin Pei, Meidong Si, Xuemei Ma, Siyun Liu, Fang Zhao, Ru ZhouNingxia Medical University and General Hospital of Ningxia Medical University.China Drug Design, Development and TherapyDrug Des Dev Ther 2025; 19: 11119-11144DOI: 10.2147/DDDT.S547530 AbstractPurpose: 18β-Glycyrrhetinic acid liposomes (18β-GA-Lips) were developed to enhance lung-specific drug delivery and optimize the therapeutic management of pulmonary arterial hypertension (PAH).Methods: 18β-GA-Lips of varying

Preparation of 18β-Glycyrrhetinic Acid Liposome and Its Therapeutic Effect on Pulmonary Arterial Hypertension Read More »

Cytochrome P450 1A1 influences obesity-induced pulmonary hypertension

Joshua P. Dignam, Smriti Sharma, Gregor Aitchison, Ayman Gebril, Ioannis Stasinopoulos, Sofia Laforest, Chelbi Coyle, Ruth Andrew, Natalie Z. M. Homer, Sébastien Bonnet, Sandra Breuils-Bonnet, Martin Wabitsch, Margaret R. MacLeanUniversity of Strathclyde. Queen Mary University of London. Medical University of Vienna. University of Edinburgh. Laval University. Ulm University Medical Center.United Kingdom, Austria, Canada and Germany

Cytochrome P450 1A1 influences obesity-induced pulmonary hypertension Read More »

Scroll to Top